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N-glycosylation-defective splice variants of
neuropilin-1 promote metastasis by activating
endosomal signals
1234567890():,;

Xiuping Huang1,2, Qing Ye2,3, Min Chen2,4, Aimin Li1, Wenting Mi1, Yuxin Fang1, Yekaterina Y. Zaytseva2,4,
Kathleen L. O’Connor2,5, Craig W. Vander Kooi2,5, Side Liu1 & Qing-Bai She 2,3

Neuropilin-1 (NRP1) is an essential transmembrane receptor with a variety of cellular functions. Here, we identify two human NRP1 splice variants resulting from the skipping of exon 4
and 5, respectively, in colorectal cancer (CRC). Both NRP1 variants exhibit increased endocytosis/recycling activity and decreased levels of degradation, leading to accumulation on
endosomes. This increased endocytic trafﬁcking of the two NRP1 variants, upon HGF stimulation, is due to loss of N-glycosylation at the Asn150 or Asn261 site, respectively.
Moreover, these NRP1 variants enhance interactions with the Met and β1-integrin receptors,
resulting in Met/β1-integrin co-internalization and co-accumulation on endosomes. This
provides persistent signals to activate the FAK/p130Cas pathway, thereby promoting CRC
cell migration, invasion and metastasis. Blocking endocytosis or endosomal Met/β1-integrin/
FAK signaling profoundly inhibits the oncogenic effects of both NRP1 variants. These ﬁndings
reveal an important role for these NRP1 splice variants in the regulation of endocytic trafﬁcking for cancer cell dissemination.
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he human neuropilin-1 (NRP1) gene encoding a transmembrane protein is located on chromosome 10p12 and
consists of 17 exons1,2. NRP1 acts as a co-receptor for
several growth factors including VEGF, TGF-β, HGF, FGF and
PDGF, and exhibits versatile functions for neuronal axon guidance, angiogenesis and cancer initiation, growth, and metastasis3–6. The multifunctional capacity of NRP1 is attributed to its
four ligand-binding domains (a1, a2, b1, b2), a membrane
proximal MAM domain (c), and a cytoplasmic C-terminal
domain5,7. NRP1 interacts with several receptor tyrosine kinases (VEGFR, Met, EGFR) and other transmembrane proteins
(integrins, plexins/semaphorins) to elicit a range of intracellular
signaling cascades initiated by speciﬁc ligands5,7–14. Upon ligand
binding, receptors are internalized by endocytosis and transported to early and late endosomes before either recycling back to
the plasma membrane or selected for degradation15. Endosomal
signaling activated by endocytosis of receptor tyrosine kinases
such as Met and EGFR play a critical role in cellular functions
including, organism development and cancer progression16–18.
Several human NRP1 variants generated by alternative splicing
mechanisms have been reported2,19–21. NRP1 splice variants
lacking the transmembrane domain are soluble proteins that bind
VEGF165, and exert anti-angiogenic and anti-tumorigenic effects
by reducing NRP1 bound to growth factors and inhibiting their
downstream signals2,19,22. In contrast, the NRP1-ΔE16 variant,
which skips exon 16, does not demonstrate any functional difference as compared to the wild type (WT) NRP121. NRP1 also
undergoes post-translational glycosylation modiﬁcations including O-linked glycosylation at site Ser61223 and N-linked glycosylation at several putative asparagine residues24,25. The O-linked
glycosylation of NRP1 at Ser612 plays an important role in the
modulation of VEGF signaling, cell proliferation and migration
and cancer invasion23,26,27. However, the role of N-linked glycosylation of NRP1 is poorly characterized and understood.
In this study, we discover two human NRP1 splice variants
from colorectal cancer (CRC) cell lines and tissue specimens. The
two NRP1 variants are generated by skipping exon 4 and exon 5,
resulting in defects in N-linked glycosylation at asparagine (N)
positions N150 and N261, respectively. The altered N-linked
glycosylation plays a critical role in regulation of the endocytic
trafﬁcking of NRP1 and its associated receptors, Met and β1integrin, for CRC cell migration, invasion and dissemination.
Furthermore, our work highlights that CRC expressing these
NRP1 splice variants could potentially be targeted by blocking
endocytosis of them and their binding receptors such as Met or
β1-integrin, or their endosomal signals on activation of the FAK/
p130Cas pathway.
Results
Identiﬁcation of two NRP1 splice variants in CRC. NRP1 acts
as a signaling hub on the cell surface and plays multifaceted roles
in multiple cancers including CRC5,22. To explore the functional
importance of NRP1 in CRC progression, we cloned NRP1 cDNA
from an HCT116 CRC cell library by RT-PCR using primers at
the 5′ and 3′ends of the full-length human WT NRP1 open
reading frame (2772 bp cDNA encoding 923 amino acids). Surprisingly, sequence analysis of NRP1 cDNA clones led to characterization of two NRP1 alternatively spliced transcripts: one
that skipped exon 4 with exon 3–5 splicing (NRP1-ΔE4, Fig. 1a, c)
and another one that skipped exon 5 with exon 4–6 splicing
(NRP1-ΔE5, Fig. 1b, c) without a shift in the reading frame. The
resulting NRP1-ΔE4 lacks 76 amino acids (position 144–219 in
the front region of the a2 domain) encoded by exon 4, and NRP1ΔE5 lacks 52 amino acids (position 220–271 in the back region of
the a2 domain) encoded by exon 5 (Fig. 1c; Supplementary
2

Fig. 1). Interestingly, the exon-intron junctions of the NRP1 gene
contain the alterative splice consensus (5′GT/AG3′) sequence1 for
generation of the NRP1-ΔE4 and NRP1-ΔE5 variants. To further
validate the existence of these variants, RT-PCR of the region that
includes exons 4 and 5 was performed with several human CRC
cell lines and a subset of CRC tissues as well as the adjacent
nonmalignant colonic mucosa using the forward primer in exon 3
and the reverse primer in exon 6. Three bands were visualized on
gel electrophoresis in HCT116 cells: the expected NRP1-WT 532bp, along with NRP1-ΔE4 376-bp and NRP1-Δ5 304-bp fragments (Fig. 1d). Notably, the abnormal NRP1 DNA fragments
were found in a subset of primary colorectal tumors (NF99,
NF103, NF105, NF106, NF110) and the primary CRC and liver
metastasis tumor cell lines (Pt93, Pt2377 and LM2377) at an
expression level equal to or above that found for NRP1-WT
mRNA (Fig. 1e, f; Supplementary Table 1). Of these, two CRC
tissues (NF99, NF106) expressed the variants as dominant NRP1
isoforms (Fig. 1e, f). In contrast, the abnormal NRP1 DNA
fragments were not detected in non-malignant colonic mucosa
even when using increased amounts of RNA for RT-PCR analysis,
whereas NRP1-WT could be detected in these normal tissues by
increasing their RNA levels (Fig. 1e; Supplementary Fig. 2a).
Direct sequencing of the RT-PCR products conﬁrmed that the
three bands correspond to NRP1-WT, NRP1-ΔE4 and NRP1-ΔE5,
respectively. Additional analysis of tumor samples from 126
patients with stage I–IV CRC showed that NRP1-ΔE4 was positively expressed in 71% of CRC tissues and signiﬁcantly enriched
with CRC progression, whereas NRP1-ΔE5 expression was
expressed less frequently (25%) and not signiﬁcantly observed as
tumors progressed through stages I–IV (Table 1; Supplementary
Table 2). Together, these ﬁndings reveal two human NRP1 splice
variants that have never been investigated, of which the NRP1ΔE4 expression correlates with CRC progression.
The NRP1 variants accumulate in intracellular compartments.
While the mRNA expression of WT NRP1 and its two splice
variants was detected in the HCT116 CRC cell line, their protein
expression was barely detected in this cell line (Supplementary
Fig. 2b). To characterize the speciﬁc function of the two NRP1
variants, the NRP1-WT, ΔE4 and ΔE5 were stably expressed at
comparable levels in HCT116 and HT29 CRC cells (Fig. 2a).
Expression of NRP1-WT, ΔE4 or ΔE5 in these cells did not affect
the protein levels of EGFR and Met receptors (Fig. 2a), whereas
VEGFR2 expression was not found in these two cell lines. NRP1WT was expressed at the plasma membrane in both cell lines with
regular culture conditions containing 10% fetal bovine serum
(FBS) as evidenced using the membrane protein α6-integrin as a
positive control (Fig. 2b, c). Interestingly, NRP1-ΔE4 and NRP1ΔE5 were expressed predominantly in punctate cytoplasmic
structures (Fig. 2b, c). Similar results were observed at 48 h after
transient transfection with the NRP1-WT and its two variants in
HCT116 and HT29 CRC cells, although the two NRP1 variants
initially localized at the plasma membrane at 24 h after the
transfection (Supplementary Fig. 2c, d). Notably, expression of
endogenous NRP1-ΔE4 and NRP1-ΔE5 proteins and their
intracellular accumulation could also be detected in the Pt93,
Pt2377 and LM2377 primary CRC cell lines; of these Pt93 cells
expressed both NRP1-ΔE4 and NRP1-ΔE5 proteins (Supplementary Fig. 2e, f). Separation procedures using a cell surface
biotinylation assay demonstrated that ~70% of the two variants
was present in the intracellular fraction compared with 5% of the
NRP1-WT (Fig. 2d, e). NRP1 is well-known as a co-receptor for
VEGF1656. In the absence of ligand, NRP1-WT, NRP1-ΔE4 and
NRP1-ΔE5 were predominantly distributed at the plasma membrane (Fig. 2f). VEGF165 largely induced the full internalization of
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Fig. 1 NRP1-ΔE4 and NRP1-ΔE5 are commonly expressed in CRC. a, b Sequencing analysis of several human NRP1 cDNA clones identiﬁed two NRP1 splice
variants: a splicing of exon 3 to exon 5 a and a splicing of exon 4 to exon 6 b. c Schematics of genomic (left) and protein (right) structures of the NRP1 gene
and the full-length WT NRP1 as well as two identiﬁed splice variants, NRP1-ΔE4 and NRP1-ΔE5. d, e RT-PCR analysis was performed on total RNA isolated
from CRC cell lines d, and normal (N1-4) and CRC tissues, as well as primary CRC cell lines e. The high, middle and low molecular weight products of 532
bp, 376 bp and 304 bp are ampliﬁed from NRP1-WT, NRP1-ΔE5 and NRP1-ΔE4, respectively. GAPDH ampliﬁcation was used as control for RT-PCR. f The
expression levels of NRP1-WT, NRP1-ΔE4 and NRP1-ΔE5 relative to GAPDH expression levels in CRC tissues as shown in e are quantiﬁed using Image J
software. The data are presented as mean ± s.e.m. (n = 3 independent experiments)

NRP1-WT from the plasma membrane to the perinuclear region,
but the two NRP1 variants showed little or no internalization
upon VEGF165 or EGF stimulation (Fig. 2f–h). In contrast, HGF,
another NRP1-binding ligand28,29 that is often overexpressed in
CRC30, markedly induced endocytosis of NRP1-ΔE4 and NRP1ΔE5, but had modest effect on the internalization of NRP1-WT
(Fig. 2f, i). Depletion of HGF from FBS using an anti-HGF
neutralizing antibody dramatically reduced the internalization of
the two NRP1 variants (Supplementary Fig. 2g, h). Collectively,
these data indicate that HGF is a critical ligand to induce

internalization of the two NRP1 splice variants and their accumulation in intracellular compartments.
The NRP1 variants shuttle between cell surface and endosomes.
We next determined the NRP1-WT, ΔE4, and ΔE5-containing
vesicular compartments by staining for several intracellular
vesicle trafﬁcking markers. Immunoﬂuorescence analysis revealed
a signiﬁcantly high level of co-localization between the
NRP1 splice variants and early endosomal antigen 1 (EEA1)
compared with NRP1-WT in HT29 cells (Fig. 3a, c). NRP1-ΔE4

NATURE COMMUNICATIONS | (2019)10:3708 | https://doi.org/10.1038/s41467-019-11580-4 | www.nature.com/naturecommunications

3

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11580-4

and NRP1-ΔE5 accumulated in the perinuclear area and colocalized more with the late endosomal marker Rab7 and three
well-known recycling endosomal markers: transferrin, Rab4 and
Rab11 (Fig. 3b, c; Supplementary Fig. 3a). No signiﬁcant colocalization was detected with lysotracker or lysosomal cathepsin
D protease (Supplementary Fig. 3b, c). Similar results were
observed in HCT116 cells expressing NRP1-WT and its two
variants (Supplementary Fig. 3d–g). Additionally, intracellular
accumulation of endogenous NRP1-ΔE4 and NRP1-ΔE5 in the
primary CRC cell lines (Pt93, Pt2377 and LM2377) was also
found in endosomes as demonstrated by co-localization with
Rab7 (Supplementary Figs. 2e, 3h). Thus, under basal conditions,
NRP1-ΔE4 and NRP1-ΔE5 localized mostly in early, late and
recycling endosomes and less on the membrane surface (Fig. 2d).
These data suggest that NRP1-ΔE4 and NRP1-ΔE5 constitutively

Table 1 Expression of NRP1-ΔE4 and NRP1-ΔE5 in CRC
NRP1-ΔE4

Stage
Stage
Stage
Stage
Total

NRP1-ΔE5

Negative Positive
18
12
11
36
3
26
4
16
36
90
p = 0.00013

I
II
III
IV

Total
30
47
29
20
126

Negative
27
34
20
13
94
p = 0.15

Positive
3
13
9
7
32

Total
30
47
29
20
126

Statistical signiﬁcance of NRP1-ΔE4 or NRP1-ΔE5 expression toward CRC progression was
determined by the χ2-test with p-value indicated
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Fig. 2 NRP1-ΔE4 and NRP1-ΔE5 accumulate in intercellular compartments. a HCT116 and HT29 cells with stable expression of NRP1-WT, NRP1-ΔE4, NRP1ΔE5 or vector control were assessed by western blot analysis. b, c Confocal images and z-stack projections of transverse sections of HCT116 b and HT29
c cells expressing the indicated NRP1 isoforms, stained for NRP1, α6-integrin and DAPI. Scale bars, 10 µm. d HT29 cells with expression of the indicated
NRP1 isoforms were surface-biotinylated, then the biotinylated proteins were pulled down by streptavidin beads. The total sample before pulldown (total),
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internalize and recycle back to the cell surface or may secrete to
the extracellular space.
To determine the rates of NRP1 internalization and subsequent
recycling, surface-biotinylated NRP1 isoforms were measured by
streptavidin-agarose pulldown after different incubation periods.
After 15 min incubation with regular culture medium, 50–73% of
the two NRP1 splice variants were internalized versus 12% of the
NRP1-WT (Fig. 3d, e). On re-incubation at 37 °C for an
additional 15 min, the remaining internalized NRP1 splice
variants were much lower when compared with NRP1-WT
(Fig. 3d), indicating that the NRP1 splice variants exhibit an
increase in their recycling activities (Fig. 3f). Notably, cycloheximide chase analysis for protein degradation showed that NRP1ΔE4 and NRP1-ΔE5 were not signiﬁcantly degraded between 0
and 8 h with regular culture medium or with HGF stimulation as
compared to the rapid degradation of NRP1-WT (Fig. 3g, h;
Supplementary Fig. 3i, j). Thus, the two NRP1 splice variants
accumulate on endosomal compartments through constitutive
shuttling between the cell surface and endosomes and display
defective degradation.

Defect in N-linked glycosylation increases NRP1 endocytosis.
Within the deleted regions of NRP1-ΔE4 or NRP1-ΔE5, we found
putative N-linked glycosylation sites at asparagine residues N150
and N261, respectively24,25 with the consensus motif, N-X-S/T31
(Supplementary Fig. 1). To determine whether N150 and N261
are speciﬁc N-linked glycosylation sites that affect endocytic
trafﬁcking of NRP1-ΔE4 and NRP1-ΔE5, respectively, NRP1
mutants in which N150 and/or N261 sites were replaced with
glutamine (Q) were expressed in HCT116 cells. Cell lysates were
treated with PNGase F, a glycosidase enzyme that hydrolyzes Nlinked oligosaccharides, and then analyzed by a migration shift
assay. We found that NRP1-WT, ΔE4, ΔE5, and N150Q and
N261Q mutants shifted downward after enzyme treatment
(Fig. 4a, b). However, the double mutant N150Q/N261Q displayed a lower molecular weight similar to that of the glycosidasetreated NRP1-WT (Fig. 4a, b). These data suggest that the Nlinked glycans were added on both N150 and N261 sites of NRP1.
Similar to the NRP1-ΔE4 and NRP1-ΔE5 variants, both
NRP1 single mutants N150Q and N261Q that were stably or
transiently (48 h) expressed in HCT116 or HT29 cells also
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accumulated in the perinuclear area and co-localized with
endosome markers EEA1 and Rab7 with no signiﬁcant degradation (Fig. 4c–f; Supplementary Fig. 4a–d). Interestingly, these
ﬁndings were obtained similarly with the double mutant N150Q/
N261Q (Fig. 4c–f; Supplementary Fig. 4a-d). By contrast, three
other putative N-glycosylation site mutants, N300Q, N522Q and
N842Q25 (Supplementary Fig. 1) and the O-linked glycosylationdeﬁcient mutant S612A23 shifted downward after treatment with
PNGase F (Fig. 4b). These mutants were expressed on the cell
surface with rapid degradation after exposure to cycloheximide
similar to NRP1-WT (Supplementary Fig. 4b–d). Furthermore,
exposure of cells to inhibitors of N-glycan synthesis (tunicamycin
or swainsonine) largely induced NRP1 accumulation in intracellular compartments, while an inhibitor of O-glycosylation
(BADGP) did not (Fig. 4g). In addition, HGF stimulation, while
not VEGF165, completely induced the endocytosis of both N150Q
and N261Q NRP1 mutants, but NRP1-WT and its mutants
N300Q, N522Q, N842Q and S612A were internalized to a lesser
extent with HGF stimulation (Supplementary Fig. 4e). Collectively, these data demonstrate that N150 and N261-linked
6

glycosylation modiﬁcation are critical in regulation of NRP1
endocytic trafﬁcking in response to HGF stimulation.
N-glycosylation-defective NRP1 promotes CRC metastasis.
NRP1 is involved in regulation of a variety of cellular functions,
such as cell proliferation, migration and invasion associated with
cancer progression5. Analysis of cell growth rate showed no signiﬁcant difference with stable expression of NRP1-WT, ΔE4 or
ΔE5 when compared to vector control in HCT116 cells (Supplementary Fig. 5a). Expression of NRP1-WT in HCT116 cells
signiﬁcantly enhanced cell migration and invasion as determined
by Boyden chamber assays and by tracking single-cell movement
with live cell imaging under basal conditions (Fig. 5a–c; Supplementary Fig. 5b, c). However, the two NRP1 splice variants
showed enhanced cell migratory and invasive capabilities (2–3
fold) when compared with NRP1-WT (Fig. 5a–c; Supplementary
Fig. 5b, c). HGF stimulation markedly enhanced cell migration in
HCT116 cells expressing NRP1-ΔE4 or NRP1-ΔE5 compared
with cells expressing NRP1-WT, whereas these effects were not
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observed with VEGF165 stimulation (Supplementary Fig. 5d).
Conversely, silencing NRP1 in Pt93 and LM2377 primary CRC
cells that express higher levels of endogenous NRP1-ΔE4 and/or
NRP1-ΔE5 than NRP1-WT (Supplementary Fig. 2e) resulted in
marked inhibition of cell migration and invasion (Supplementary
Fig. 5e-g). Similar to the NRP1-ΔE4 and NRP1-ΔE5 variants,
both N-glycosylation-defective NRP1 mutants N150Q and
N261Q profoundly enhanced cell migration and invasion compared to NRP1-WT (Fig. 5d–f). By contrast, the double mutant
N150Q/N261Q showed no enhancement in these capabilities
when compared with either of the single mutants (Fig. 5d–f). To
determine whether the NRP1 variants facilitate cancer metastasis,
we used an experimental lung metastasis model in vivo.
Luciferase-labeled HCT116 cells with stable expression of NRP1WT, NRP1-ΔE4, NRP1-ΔE5 or vector control were injected
intravenously into athymic nude mice, and lung metastasis was

assessed by bioluminescent imaging. Compared to NRP1-WT
and vector control, expression of either of the NRP1 splice variants remarkably promoted lung metastases in mice (Fig. 5g, h).
Thus, these ﬁndings reveal an important role of the NRP1 splice
variants in CRC cell dissemination.
Met and β1-integrin co-internalize with the NRP1 variants.
NRP1 interacts with the tyrosine kinase receptor Met and β1integrin to increase malignant transformation activity10,12,13.
Considering that both Met and β1-integrin play important roles
in CRC progression and metastasis30,32,33, we examined the
possible difference between NRP1-WT and its splice variants in
the interaction and co-localization with Met and β1-integrin in
CRC cells. Co-immunoprecipitation analysis showed that,
compared with NRP1-WT, the two NRP1 variants had greater
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interaction with both the precursor (p-170) and mature β-chain
(p-145) forms of Met, as well as with β1-integrin (Fig. 6a, b).
Remarkably, immunoﬂuorescence staining and separation
procedures using a cell surface biotinylation assay revealed that
Met was highly internalized and co-localized with the two
8
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NRP1 variants in intracellular compartments (Fig. 6c, d; Supplementary Fig. 6a, b). By contrast, Met co-localized with
NRP1-WT on the plasma membrane (Fig. 6c, d). Interestingly,
active β1-integrin (12G10 antibody)34 was also visible predominantly in punctate cytoplasmic structures and largely
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Fig. 6 Met and β1-integrin co-internalize with the NRP1 variants for CRC cell dissemination. a HT29 cells with stable expression of NRP1-WT, NRP1-ΔE4 or
NRP1-ΔE5 were lysed and immunoprecipitated with NRP1 antibody or IgG as control followed by western blot analysis. b Quantiﬁcation of Met or β1intergrin interaction with NRP1-WT and the splice variants through densitometric analysis of bands from western blots a using Image J software. c Confocal
images of NRP1, Met, active β1-integrin and DAPI staining in HCT116 cells with expression of the indicated NRP1 isoforms. Scale bars, 10 µm.
d Quantiﬁcation of co-localization between Met or β1-integrin and the indicated NRP1 isoforms as shown in c. e–g NRP1-ΔE4- or NRP1-ΔE5-expressing
HCT116 cells with stable expression of NRP1 shRNA, Met shRNA, β1-integrin shRNA or control shRNA were assessed by western blot analysis e or by
confocal sections of the cells stained for NRP1, Met, β1-integrin, Rab7 and with DAPI f, g. Scale bars, 10 µm. h, i NRP1-ΔE4- or NRP1-ΔE5-expressing HT29
cells with transient expression of GIPC1 siRNA or control siRNA were assessed by western blot analysis h or by confocal sections of the cells stained for
NRP1, Met, β1-integrin and DAPI i. Scale bars, 10 µm. j, k NRP1-WT-, NRP1-ΔE4- or NRP1-ΔE5-expressing HCT116 cells with stable expression of two
different sets of Met shRNA, β1-integrin shRNA or control shRNA were assessed by transwell migration j and invasion k analyses over 6 h and 30 h
of incubation, respectively. The results are expressed as the inhibition of cell migration or invasion relative to each of the shCtrl-expressing cells.
l Bioluminescence images of lung metastasis in athymic nude mice that were injected intravenously with NRP1-ΔE4-expressing HCT116-Luciferase/GFP
cells with stable expression of Met shRNA, β1-integrin shRNA or control shRNA at week 6 post-injection. m Quantitative analysis of bioluminescence in
lung metastasis as shown in l was performed, and the results are presented as mean ± s.e.m. (n = 6 mice/group). The graphic data in b, d, j, k are
presented as mean ± s.e.m. (n = 3 independent experiments). *p < 0.005; #p < 0.03 using Student’s t-test; **p < 0.005 using Mann–Whitney test

co-localized with both NRP1 variants and Met in the perinuclear area (Fig. 6c, d). However, active β1-integrin co-localized with NRP1-WT and Met on the plasma membrane in
NRP1-WT-expressing cells under basal conditions (Fig. 6c, d).
Similar results were observed in primary CRC cell lines (Pt93,
Pt2377, LM2377) that express endogenous NRP1-ΔE4 and/or
-ΔE5 (Supplementary Figs. 2e, 6c, d, 7a) and in HT29 cells
expressing the N-glycosylation-defective NRP1 mutant N150Q
or N261Q (Supplementary Figs. 6e, 7b). Upon HGF but not
VEGF165 stimulation, Met also internalized, accumulated in the
perinuclear area, and co-localized with the two NRP1 variants
and NRP1 mutants N150Q and N261Q (Supplementary
Fig. 6f). Moreover, Met protein levels were stable in HCT116
cells expressing either the NRP1 variants or mutants as compared to its rapid degradation in the NRP1-WT-expressing cells
after treatment with cycloheximide (Supplementary Fig. 6g, h);
whereas β1-integrin levels were relatively stable in the cells
expressing either NRP1-WT or its variants or mutants (Supplementary Fig. 7c, d). To determine whether the internalization of Met and β1-integrin is dependent on binding to the
NRP1 variants, NRP1-ΔE4 and NRP1-ΔE5 were knocked down
transiently or stably by RNAi. Silencing of either NRP1-ΔE4 or
NRP1-ΔE5 expression in HCT116 and HT29 cells completely
prevented the internalization of Met and β1-integrin, but had
no effect on Met/β1-integrin interaction (Fig. 6e–g; Supplementary Figs. 6i–k). Notably, knockdown of either Met or β1integrin expression did not alter the accumulation of NRP1ΔE4 or NRP1-ΔE5 on endosomes or protein stability 8 h after
cycloheximide exposure (Fig. 6e–g; Supplementary Figs. 6l, m,
7e, f). However, knockdown of Met caused β1-integrin
dissociation from the endosomal NRP1 variants, whereas
knockdown of β1-integrin had no effect on Met interaction and
co-localization with the NRP1 variants on endosomes
(Fig. 6e–g; Supplementary Fig. 7g). GIPC1 is a well-known
NRP1 interacting protein via direct binding to the SEA motif in
the intracellular domain of NRP135, and couples NRP1 to other
signaling receptors, including VEGFR and integrins, to accelerate their endocytosis13,36. Silencing GIPC1 largely abrogated
the internalization of the two NRP1 variants as well as the cointernalization of Met and β1-integrin in the NRP1 variantexpressing cells under basal conditions (Fig. 6h, i). Taken
together, these data indicate that internalization of NRP1-ΔE4
and NRP1-ΔE5 and their accumulation on endosomes are
independent of Met or β1-integrin activity. Conversely, internalization of Met and β1-integrin and their accumulation on
endosomes are controlled by the NRP1 variants and the adaptor
protein GIPC1.

Notably, silencing of either Met or β1-integrin profoundly
inhibited cell migration and invasion (~80%) in HCT116 cells
expressing NRP1-ΔE4 or NRP1-ΔE5, compared to the modest
inhibition (~20%) observed in the cells expressing NRP1-WT
(Fig. 6j, k). Given that endosomal Met-mediated Rac1 activation
has been shown to enhance cell migration17, we examined
whether the NRP1 variants that lead to Met internalization on
endosomes also activate Rac1. We found that Rac1 was
substantially activated in HCT116 cells expressing NRP1-ΔE4
or NRP1-ΔE5 in regular growth medium or upon HGF
stimulation (Supplementary Fig. 8a, b), and silencing Rac1
profoundly inhibited cell migration in these cells (Supplementary
Fig. 8c, d). Furthermore, lung metastasis induced by NRP1-ΔE4
in vivo was also dramatically repressed by knockdown of either
Met or β1-integrin expression (Fig. 6l, m). These ﬁndings
highlight that both Met and β1-integrin function as key partners
of the NRP1 variants in endosomes to promote cell migration,
invasion and metastasis.
Endocytosis is required for the NRP1 variants’ activities.
Clathrin-dependent and Clathrin-independent endocytosis
require the activity of dynamin, a GTPase responsible for
pinching vesicles from the plasma membrane and thereby driving
internalized cargo into carrier vesicles15. To determine if endocytosis of the NRP1 variants, Met and β1-integrin are dependent
on dynamin, HCT116 cells were treated with the dynamin inhibitor, dynasore37, or transfected with a dynamin dominantnegative construct (dynamin-2 K44A-GFP). Treatment with
dynasore or expression of the dynamin-2 K44A mutant increased
the levels of the NRP1 variants, Met and β1-integrin at the plasma
membrane with a concomitant decrease in their intracellular
pools (Fig. 7a, b and Supplementary Fig. 9a). Moreover, cell
migration and invasion were dramatically inhibited by dynasore
in HCT116 cells expressing either of the two NRP1 variants but
not NRP1-WT (Fig. 7c, d). Similar results were observed in
HCT116 cells knocked down for clathrin heavy chain (CHC)
(Fig. 7e–h; Supplementary Fig. 9b). Thus, these results reveal that
internalization of the NRP1 variants, Met and β1-integrin and
their complex formation to enhance cell migration and invasion
are mediated by dynamin- and clathrin-dependent endocytosis.
The NRP1 variants activate FAK signaling in endosomes. To
determine which pathways are involved in the endosomal
NRP1 splice variant/Met/β1-integrin complex-promoted CRC
cell dissemination, activation of Met and its downstream PI3K/
AKT, RAS/ERK and FAK/p130Cas signaling cascades, were
examined in HCT116 cells expressing NRP1-WT, NRP1-ΔE4,
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Fig. 7 Blocking endocytosis of the NRP1 variants inhibits CRC cell migration and invasion. a Confocal images of NRP1, Met and DAPI staining in HT29 cells
with expression of the indicated NRP1 isoforms that were treated with dynasore (80 µM) or DMSO as control for 2 h. Scale bars, 10 µm. b Confocal images
of NRP1 with DAPI staining in NRP1-ΔE4- or NRP1-ΔE5-expressing HCT116 cells that were transfected with WT dynamin-2-GFP or dynamin-2 K44A-GFP.
Scale bars, 10 µm. c, d Transwell migration c and invasion d analyses of HCT116 cells with expression of the indicated NRP1 isoforms in the presence of
DMSO or dynasore (80 µM) over 6 h and 30 h of incubation, respectively. The results are expressed as the fold change of cell migration or invasion in the
indicated cells relative to the NRP1-WT-expressing cells treated with DMSO. e Confocal images of NRP1, Met and DAPI staining in HT29 cells with
expression of the indicated NRP1 isoforms that were transfected with two different sets of CHC siRNA or control siRNA. Scale bars, 10 µm. f–h HCT116 cells
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independent experiments). *p < 0.001; NS not signiﬁcant using Student’s t-test

NRP1-ΔE5 or vector control. Expression of either NRP1-ΔE4 or
NRP1-ΔE5 markedly increased Met phosphorylation levels of
Y1234/1235 (kinase domain) and Y1349 (docking site) over that
seen for NRP1-WT (Fig. 8a), which suggests enhanced kinase
10

activity of Met. Similarly, the phosphorylation levels of FAK at
Y397 and its interacting protein p130Cas at Y249 were also much
higher in both NRP1-ΔE4 and NRP1-ΔE5 relative to the NRP1WT (Fig. 8a). These effects were not due to an increase in the
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Rab7 and DAPI staining in HCT116 cells with expression of the indicated NRP1 isoforms. Scale bars, 10 µm. e NRP1-WT-, NRP1-ΔE4- or NRP1-ΔE5expressing HCT116 cells with stable expression of two different sets of β1-integrin shRNA or control shRNA were assessed by western blot analysis. f NRP1ΔE4- or NRP1-ΔE5-expressing HCT116 cells were treated with DMSO or dynasore (80 µM) for 2 h, followed by western blot analysis. g NRP1-ΔE4- or
NRP1-ΔE5-expressing HCT116 cells were transfected with clathrin heavy chain (CHC) siRNA or control siRNA for 48 h, followed by western blot analysis.
h, i HCT116 cells with expression of the indicated NRP1 isoforms were transfected with two different sets of FAK siRNA or control siRNA for 48 h, followed
by western blot analysis h, or by transwell migration analysis i. The results are expressed as the fold change over the migrated cell number found in NRP1WT cells transfected with siCtrl. Data are presented as mean ± s.e.m. (n = 3 independent experiments). *p < 0.03; **p < 0.001 using Student’s t-test.
j Western blot analysis of NRP1-ΔE4-expressing HCT116-Luciferase/GFP cells with stable expression of FAK shRNA or control shRNA. k Bioluminescence
images of lung metastasis in athymic nude mice that were injected intravenously with NRP1-ΔE4-expressing HCT116-Luciferase/GFP cells with stable
expression of FAK shRNA or control shRNA at week 6 post-injection. This experiment was performed by sharing the same shCtrl group with the experimet
performed in Fig. 6l, m. l Quantitative analysis of bioluminescence in lung metastasis as shown in k was performed, and the results are presented as mean
± s.e.m. (n = 6 mice/group). ***p < 0.005 using Mann–Whitney test
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Fig. 9 A model for NRP1-WT and its splice variants signaling in CRC cell dissemination. a NRP1-WT associates with Met and β1-integrin receptors and
resides on plasma membrane (PM) under basal conditions, and internalizes upon stimulation by HGF followed by rapid degradation, leading to a restricted
period of signal generation. b NRP1-ΔE4 or NRP1-ΔE5 renders Met and β1-integrin co-internalization and constitutively recycles back to the cell surface or
the extracellular space under basal conditions. These events result in an increased accumulation of the NRP1 variants/Met/β1-integrin complexes on
endosomes, which provides persistent endosomal signals to activate the FAK/p130Cas pathway for promoting cell migration, invasion and metastasis in
CRC. These oncogenic activities of NRP1-ΔE4 or NRP1-ΔE5 are further enhanced by HGF stimulation

total levels of Met, FAK and p130Cas in the cells expressing
NRP1-ΔE4 or NRP1-ΔE5. By contrast, there were no detectable
differences in the expression of total protein and phosphorylation
levels of AKT and ERK among those cell lines (Fig. 8a). Knockdown of Met expression effectively inhibited phosphorylation of
FAK and p130Cas in HCT116 cells expressing either NRP1-ΔE4,
NRP1-ΔE5 or NRP1-WT (Fig. 8b). However, complete inhibition
of Met phosphorylation by the Met speciﬁc inhibitor, PHA66575238, did not affect phosphorylation level of FAK, p130Cas,
AKT, or ERK (Supplementary Fig. 10a). Consistent with the view
that Met internalization depends on its tyrosine kinase activity39,
PHA-665752 did inhibit HGF-induced MET internalization in
HCT116 cells (Supplementary Fig. 10b). Nevertheless, PHA665752 did not affect the co-internalization of the NRP1 variants/
Met/β1-integrin complex under basal conditions (Supplementary
Fig. 10c). Unlike the marked inhibition of cell migration and
invasion by Met knockdown in NRP1-ΔE4- or NRP1-ΔE5expressing cells (Fig. 6j, k), treatment with PHA-66575 had no
such effects (Supplementary Fig. 10d, e). Similar to the reported
activation of FAK by endosomal β1-integrin34, active β1-integrin,
phosphorylated FAK and NRP1-ΔE4 or NRP1-ΔE5 co-localized
on endosomes (Fig. 8c, d), and silencing β1-integrin also dramatically inhibited phosphorylation of FAK and p130Cas in these
cells (Fig. 8e). Furthermore, blocking endocytosis by treatment
with dynasore or knockdown of CHC expression did not inhibit
phosphorylation of Met, but did decrease the phosphorylation
levels of FAK and p130Cas in cells expressing NRP1-ΔE4 or
NRP1-ΔE5 (Fig. 8f, g). Collectively, these results indicate that
both Met and β1-integrin proteins, but not Met tyrosine kinase
activity, are required for endosomal activation of FAK/p130Cas
signaling induced by the NRP1 variants.
Silencing FAK using siRNA or treatment with the FAK speciﬁc
inhibitor VS-6063 that inhibits phosphorylation of both FAK and
p130Cas, showed a greater inhibition of cell migration and
12

invasion in HCT116 cells expressing NRP1-ΔE4 or NRP1-ΔE5
than in those expressing NRP1-WT (Fig. 8h, i; Supplementary
Fig. 10f-h). Similar results were observed in HCT116 cells with
knockdown of p130Cas expression (Supplementary Fig. 10i, j).
Additionally, knockdown of FAK expression showed marked
suppression of lung metastasis induced by NRP1-ΔE4 in mice
(Fig. 8j–l). Thus, the persistent activation of FAK/p130Cas
signaling and promotion of CRC cell dissemination are linked
directly to enhanced endocytic trafﬁcking of the NRP1 variants/
Met/β1-integrin complex and its accumulation and signaling on
endosomes (Fig. 9, model).
Discussion
NRP1 is overexpressed in a range of human cancers including
CRC, and increased expression of NRP1 is associated with poor
patient prognosis22,40. Characterization of the NRP1 variants
generated by alternative splicing mechanisms and modiﬁcation of
NRP1 by O-linked glycosylation have provided profound insights
into our understanding of the regulation of NRP1 function in
cancer growth, angiogenesis, invasion, metastasis and modulation
of therapeutic outcomes5,22,41. Here, our ﬁndings add two human
NRP1 splice variants generated by the skipping of exon 4 and
exon 5, respectively, in CRC. While the NRP1-ΔE4 is dominantly
expressed in CRC associated with tumor progression, both
NRP1 splice variants are defective in N-linked glycosylation
modiﬁcation, and exhibit increased endocytosis/recycling activity
with decreased levels of degradation, which lead to their accumulation on endosomes and persistent activation of FAK/
p130Cas signaling through interaction and co-internalization
with Met and β1-integrin. This perturbed trafﬁcking of the two
NRP1 splice variants promotes CRC cell migration, invasion and
metastasis, directly linking endocytosis and metastatic progression (Fig. 9).

NATURE COMMUNICATIONS | (2019)10:3708 | https://doi.org/10.1038/s41467-019-11580-4 | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11580-4

Ligand-induced endocytosis of signaling receptors is an
important mechanism for negatively regulating signaling from
the cell surface through rapid internalization and subsequent
transport to late endosomes and lysosomes for degradation15.
However, a growing body of evidence indicates that receptors
such as EGFR and Met receptor tyrosine kinases (RTKs) or β1integrin can remain active within endosomes to provide spatially
and temporally restricting signals that contribute to pathwayspeciﬁc tumor progression16,17,34,42–44. NRP1 lacks a typical
kinase domain, primarily functioning as a co-receptor to form
ligand-speciﬁc receptor complexes7. Our data are consistent with
the view10 that NRP1-WT associates with the Met receptor and
resides on the plasma membrane, and that they co-internalize
upon stimulation by HGF, but not VEGF, followed by rapid
degradation in CRC cells (Fig. 9a). It is noteworthy that NRP1ΔE4, NRP1-ΔE5 and the N-glycosylation-defective NRP1
mutants N150Q and N261Q also localized on cell surface 24 h
after transient or stable expression under serum-free conditions.
These data suggest that altered N-glycosylation modiﬁcation does
not affect NRP1 transport to the plasma membrane after its
synthesis. However, HGF stimulation even with low levels of
HGF under basal conditions can markedly induce endocytosis of
the NRP1 splice variants or N150Q and N261Q mutants together
with Met and β1-integrin receptors (Fig. 9b). Unlike NRP1-WT,
the NRP1 splice variants display enhanced binding capabilities
with both Met and β1-integrin to form the NRP1 variants/Met/
β1-integrin complexes, leading to co-internalization and coaccumulation on late endosomes. These endosomal complexes
provide persistent signals to activate the FAK/p130Cas pathway,
and thereby, promote CRC cell migration, invasion and metastasis. These effects were not induced by VEGF165 stimulation.
Structurally, the b1/b2 domain of NRP1 is required for binding to
VEGF165, whereas the presence of a1/a2 domain in NRP1
enhances VEGF165 binding considerably45. NRP1 can also bind to
HGF, which is likely mediated through its b1/b2 domain28. Given
our ﬁndings that (1) NRP1-ΔE4 and NRP1-ΔE5 lack a part of a2
domain with defective N-glycosylation modiﬁcation at the sites
N150 and N261, respectively, and had modest internalization
upon VEGF165 stimulation; and (2) the other three putative Nglycosylation-defective mutants, N300Q, N522Q and N842Q, or
the O-linked glycosylation-deﬁcient S612A mutant did not affect
NRP1 localization on the plasma membrane and were less
responsive to HGF stimulation, we propose that the partial
deletion of a2 domain or defect in N150- or N261-linked glycosylation modiﬁcation may reduce NRP1 binding to VEGF165, but
enhance its binding to HGF, which results in the observed
enhancement in HGF-stimulated endocytosis even in cells with
depletion of Met or β1-integrin under basal conditions (Fig. 6f, g).
Although this notion requires further investigation, the current
study reveals a critical role for N150- or N261-linked glycosylation modiﬁcation in the regulation of HGF-stimulated NRP1
endocytosis and activation of endosomal signaling that contribute
to CRC metastatic spread. The NRP1 S612A mutant, deﬁcient in
O-linked glycosylation, was previously shown to enhance cell
invasion of U87MG glioma cells by increasing p130Cas phosphorylation, but the underlying mechanism is unclear26. Interestingly, we found that similar to NRP1-WT, the NRP1 S612A
mutant was unstable compared to the NRP1 N150Q or N261Q
mutants (Supplementary Fig. 4c, d). Whether a defect in N-linked
glycosylation of NRP1 is more aggressive than in O-linked glycosylation of NRP1 to promote metastatic progression is another
matter that remains to be further characterized.
The enhanced level of endocytosis/recycling of the two NRP1
metastasis-promoting variants, along with their impaired degradation, indicates that they undergo a persistent shuttling between
the cell surface and endosomes. Such shuttling of ligand-

ARTICLE

stimulated RTKs and integrins has been shown to regulate the
spatial restriction of signaling necessary for directed
migration17,46,47. Although a small amount of the cell surfacebiotinylated NRP1-ΔE4 and NRP1-ΔE5 was detected using the
streptavidin-agarose pulldown analysis (Fig. 2d), these variants
were barely detected on plasma membrane under basal conditions
by immunoﬂuorescence analysis (Fig. 2b, c). These data suggest
that the two NRP1 variants are rapidly internalized after recycling
back to the cell surface and/or they may transport to the extracellular space by secreted exosomes. Exosomes are vesicles
derived from late endosomes, also known as multivesicular
bodies, and can be secreted to the extracellular environments by
most cell types48,49. Indeed, we found that the two NRP1 variants
also co-localized with several common exosome marker proteins,
including CD63, CD81 and Alix50 (Supplementary Fig. 11).
Exosomes are key mediators of intercellular communication and
can be detected in the tumor microenvironment. Emerging evidence suggests that exosomes play an important role in facilitating tumorigenesis by regulating angiogenesis and
metastasis48,51. Thus, it is likely that the NRP1 variants are
secreted by exosomes and continuously internalize and sustain
the active NRP1 variants/Met/β1-integrin complexes on endosomes, and thereby, provide persistent endosomal signals for
tumor progression.
The increased endocytotic activity of the NRP1 variants/Met/
β1-integrin complexes is dependent on GIPC1, clathrin and
dynamin, but is independent of Met activity, because the internalization of these complexes was not affected by a Met-speciﬁc
tyrosine kinase inhibitor. Silencing Met or β1-integrin also does
not affect internalization of the NRP1 splice variants, but depletion of the NRP1 variants blocks endocytosis of both Met and β1integrin. While regulation of the endocytosis of the NRP1 variants/Met/β1-integrin complexes need further characterization,
our results strongly suggest that the physical interaction with the
NRP1 variants and NRP1 adaptor protein GIPC1 are required for
co-internalization of Met and β1-integrin under the basal condition with low levels of HGF. On the other hand, the NRP1
variants also require both Met and β1-integrin as partners in
endosomes for sustained activation of the FAK/p130Cas signaling
pathway to promote CRC cell dissemination. While Met has been
shown to directly bind FAK leading to FAK activation in a Met
phosphorylation-dependent manner52, active β1-integrin can also
positively regulate FAK activity on endosomes34. In addition,
several studies highlight an important role for the cross-activating
Met/β1-integrin complex in promotion of cancer invasion and
metastasis53–55. Our current study shows that pharmacological
inhibition of Met had no effect on FAK activation and cell
migration and invasion in CRC cells expressing the NRP1 variants and suggests that β1-integrin bypass signaling contributes to
FAK activation and renders Met tyrosine kinase inhibitorresistant in these cells. Indeed, silencing β1-integrin profoundly
inhibited FAK/p130Cas signaling for CRC cell motility and
metastasis, and similar results were observed for Met knockdown
that caused active β1-integrin to dissociate from endosomal
NRP1 variants. Thus, our ﬁndings highlight the functional
importance of the NRP1 variants/Met/β1-integrin complexes on
endosomes in activating FAK signaling for CRC metastasis.
Strikingly, blocking endocytosis of these complexes by pharmacological or genetic blockers of endocytosis or by silencing clathrin expression in the NRP1 variant-expressing cells markedly
decreased FAK/p130Cas signaling as well as the migratory and
invasive phenotypes. Similar results were observed by genetic or
pharmacological inhibition of FAK/p130Cas signaling. Thus,
strategies aimed at blocking endocytosis or formation of NRP1
variants/Met/β1-integrin complexes or alternatively inhibiting
their endosomal signals on activation of FAK/p130Cas pathway
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using pharmacological inhibitors of FAK, may have therapeutic
potential in CRC and possibly other types of cancers with
expression of the N-glycosylation-defective NRP1 splice variants.
Methods
Cell lines and human CRC specimens. Human HCT116, HT29 and DLD-1 cell
lines were obtained from American Type Culture Collection (ATCC). HCT116 and
HT29 cells were cultured in McCoy’s medium (Sigma). DLD-1 cells were cultured
in RPMI-1640 medium (Sigma). Primary human CRC cell lines, Pt93 and Pt130, as
well as Pt2337 and its paired liver metastasis cell line, LM2377, were established
from patient primary and metastatic tumors (Markey Cancer Center, University of
Kentucky)56. The primary CRC cells were cultured in DMEM medium (Sigma). All
media were supplemented with 10% FBS (Sigma), streptomycin (100 µgml−1) and
penicillin (100 unitsml−1). All cell lines were subjected to regular mycoplasma
testing via PCR using e-Myco Plus kit (iNtRON Biotechnology) and underwent
short tandem repeat (STR) proﬁling (Genetica). The 126 frozen fresh primary
colorectal tumors including NF90, NF99, NF103, NF105, NF106, and NF110 and
adjacent normal control tissues (N1-4) were collected from patients who had
undergone surgery resections at the Nanfang Hospital, Southern Medical University, China and the Markey Cancer Center, University of Kentucky. Experiments
were performed under protocols approved by the Southern Medical University
Ethics Committee and the University of Kentucky Institutional Review Board. All
CRC cases were conﬁrmed by a senior pathologist and staged based on the 2011
Union for International Cancer Control TNM classiﬁcation of malignant tumors.
The pathological diagnoses of all enrolled patients were conﬁrmed by two different
pathologists according to the WHO grading system57. Data regarding the clinical
characteristics of patients are listed in Supplementary Tables 1 and 2.
Growth factors and chemicals. VEGF165, EGF, and HGF were purchased from
R&D Systems. LysoTracker Deep Red was purchased from ThemoFisher Scientiﬁc.
Cycloheximide, tunicamycin, swainsonine, benzyl 2-acetamido-2-deoxy-α-Dgalactopyranoside (BADGP) and dynasore were obtained from Sigma. PHA665752 was purchased from Selleckchem. VS-6063 was purchased from MedChem
Express.
RT-PCR. Total RNA was isolated from cells using the RNeasy plus mini kit
(Qiagen), and from tissues using TRIzol reagent (ThermoFisher Scientiﬁc),
according to the manufacturer’s instructions. Equal amounts of RNA were used as
templates for all reactions. cDNA was generated with the SuperScript III First
Strand Synthesis System (ThermoFisher Scientiﬁc). PCR was performed using the
Phusion Hot Start II High-Fidelity DNA Polymerase kit (ThermoFisher Scientiﬁc).
The primers 5′-TACGAAACACATGGTGCAGGA-3′ (forward) and 5′-CTGCAG
ACCAGTTGGTGCTAT-3′ (reverse) were used to amplify NRP1-WT, NRP1-ΔE4
and NRP1-ΔE5 in the human samples. The ampliﬁed PCR fragments were separated on an agarose gel and subjected to DNA sequencing. Primers 5′- ACAACTT
TGGTATCGTGGAAGG -3′ (forward) and 5′-GCCATCACGCCACAGTTTC-3′
(reverse) were used to amplify human GAPDH.
Plasmids. Human NRP1-WT, NRP1-ΔE4 and NRP1-ΔE5 were ampliﬁed by PCR
using a HCT116 cDNA library, and then subcloned into the pLenti6.3 or pCMV6
vector58,59. The NRP1 mutants N150Q, N261Q, N150Q/N261Q, N300Q, N522Q,
N842Q and S612A were generated using a QuikChange XLII mutagenesis kit
(Stratagene). All sequences were veriﬁed by automated DNA sequencing. To
establish stable transfectants with speciﬁc protein expression, cells were infected
with lentivirus using the indicated pLenti6.3 constructs followed by selection with
puromycin (2 µgml−1) for 7–10 days58. Dynamin-2 K44A-GFP (#34687) and WT
dynamin-2-GFP (#34686) were purchased from Addgene.
Gene silencing by siRNA and shRNA. The siRNA against human NRP1 (#79833,
#79835), clathrin (#34735, #34736), FAK (#34733, #34734), p130Cas (#34731,
#34732) and non-targeting control siRNA (#0207) were obtained from GenePharma. The ON-TARGETplus human GIPC1 siRNA pool (L-019997-00-0005)
and non-targeting control siRNA pool (D-001810-10) were purchased from
Dharmacon. Cells were transfected with 50 nM siRNA against the indicated genes
or control siRNA using Lipofectamine RNAiMAX reagent according to the manufacturer’s instructions (ThermoFisher Scientiﬁc). After 36–48 h transfection, cells
were utilized for the indicated assays. The lentiviral shRNAs against human NRP1,
Met, β1-integrin or FAK were cloned into the pLKO.1 vector (Sigma). The NonTarget Control shRNA (SHC002) was from Sigma. Both siRNA and shRNA
sequences are listed in Supplementary Table 3. To establish stable transfectants
with knockdown of speciﬁc protein expression, cells were infected with lentivirus
using the indicated shRNA constructs followed by selection with hygromycin
(250 µgml−1) for 7–10 days58.
Immunoﬂuorescence and confocal microscopy analysis. Cells (5 × 104) were
grown on collagen-precoated coverslips in the regular growth medium containing
10% FBS, or serum starved overnight followed by stimulation with VEFG165
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(50 ngml−1), EGF (50 ngml−1) or HGF (50 ngml−1) for 30 min. Subsequently, cells
were ﬁxed with 4% paraformaldehyde in PBS for 15 min, permeabilized in 0.2%
Triton X-100 and 0.5% BSA in PBS for 5 min and then blocked with 4% BSA in
PBS for 10 min. The cells were incubated overnight at 4 °C with the indicated
primary antibody. After three washes with 0.05% Triton X-100 in PBS, cells were
incubated with the indicated secondary antibody for 1 h. Cells were then washed
three times, mounted with DAPI containing mounting medium (H-1200, Vector
Laboratories), viewed, and photographed under a Nikon A1+-Ti2 confocal
microscope. For image quantiﬁcations, picture ﬁelds were chosen arbitrarily on the
basis of DAPI staining. For the NRP1 variant and mutant intracellular localization
and co-localization experiments, ten pictures were taken per condition. The percentages of co-localizations were determined using Nikon NIS-Elements AR software. The primary and secondary antibodies used in this assay are listed in
Supplementary Table 4.
Immunoprecipitation and western blot analysis. Cells were lysed in RIPA buffer
(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 0.5%
sodium deoxycholate, 10% glycerol, protease and phosphatase inhibitor cocktails).
Protein concentrations were measured using the BCA protein assay reagent
(Thermo Fisher Scientiﬁc). The cell lysates (500 µg protein) were immunoprecipitated with 2 µg of the indicated antibody overnight followed by incubation with a
50% slurry of protein G sepharose beads for 3 h at 4 °C. The beads were washed
three times with the lysis buffer, and the immunoprecipitated protein complexes
were resuspended in 2× Laemmli sample buffer followed by western blot analysis.
For western blot analysis, equal amounts of protein were resolved by SDS-PAGE,
transferred to PVDF membranes, immunoblotted with speciﬁc primary and secondary antibodies, and detected using chemiluminescence (GE Healthcare). A list
of all antibodies used in this work and dilutions can be found in Supplementary
Table 4. Contrast of western blot images was adjusted using Adobe Photoshop and
uncropped and unprocessed scans are found in the Source Data ﬁle.
Detection of NRP1 N-glycosylation. Cells were lysed in RIPA buffer, and the cell
lysates were treated with PNGase F (peptide N-glycosidase F) for 3 h at 37 °C
according to the manufacturer’s instructions (#P0704, New England Biolabs). The
reaction was stopped by the addition of 5 × loading buffer followed by western blot
analysis using anti-NRP1 antibody (#3725, Cell Signaling Technology).
Cell surface biotinylation assay. To measure the relative proportions of the cell
surface and internal pools of NRP1, cell surface proteins were labeled covalently
using a membrane-impermeable biotinylation reagent (N-hydroxysulphosuccinimide (sulpho-NHS)-SS-biotin; ThermoFisher Scientiﬁc) according
to the protocol described by Joffre et al.17. Brieﬂy, cells were incubated with
0.15 mg ml−1 biotin for 10 min at 4 °C and the excess biotinylation reagent was
quenched by washing with the cold buffer containing 25 mM Tris at pH 8, 137 mM
NaCl, 5 mM KCl, 2.3 mM CaCl2, 0.5 mM MgCl2 and 1 mM Na2HPO4. Cells were
lysed in RIPA buffer and centrifuged. A fraction of the supernatant (total cellular
NRP1 or Met = ‘total’) was collected. The residual supernatant was added to prewashed streptavidin-agarose beads (ThermoFisher Scientiﬁc) and rotated at 4 °C
for 2 h. Beads were collected by centrifugation and the supernatant (internal pool of
NRP1 or Met = ‘unbound’) was collected. Beads were washed 3 times with the
RIPA buffer at 4 °C and proteins (surface pool of NRP1 or Met = ‘bound’) were
extracted by heating at 95 °C with sample buffer. Equivalent volumes were analyzed
by western blot and densitometric analyses were carried out. The percentage of
intracellular NRP1 or Met was calculated using the formula: intracellular NRP1 or
Met receptor = (NRP1 or Met in unbound fraction)/(total NRP1 or Met) × 100.
Biotinylation internalization and recycling assay. The trafﬁcking assay for NRP1
and its variants was performed according to the method described by Joffre et al.17.
Cells were cultured in serum-free medium overnight followed by washing with cold
PBS. On ice, cell surface proteins were labeled with 0.2 mgml−1 NHS-SS-biotin in
PBS for 45 min. Labeled cells were washed with cold PBS and incubated at 37 °C in
culture medium containing 10% FBS, to allow protein trafﬁcking. At the indicated
times, the medium was aspirated and the dishes were transferred to ice and washed
with cold PBS. Biotin was removed from proteins remaining at the cell surface by
reduction with 180 mM of the membrane-impermeable reducing agent MesNa
(sodium 2 mercaptoethane sulphonate, Sigma) in 50 mM Tris and 100 mM NaCl at
pH 8.6 for 15 min. MesNa was quenched by the addition of 180 mM iodoacetamide
(IAA, Sigma) for 10 min.
To measure internalized NRP1 and its variants, the assay was terminated by
lysing the cells. Lysates were passed three times through a 27-gauge needle and
clariﬁed by centrifugation (17,000 g). Equal protein amounts were incubated with
streptavidin-agarose beads with agitation at 4 °C for 2 h. The beads were collected
by centrifugation (7,000 g), washed in lysis buffer and proteins were extracted by
heating at 95 °C with sample buffer.
To measure the proportion of internalized NRP1 proteins and the variants that
recycle back to the cell surface, the internalized fraction was returned to 37 °C for
15 min as a chase. Cells were then returned to ice and biotin was removed from
recycled proteins by a second reduction with MesNa. Unreacted MesNa was
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Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.

quenched with IAA and cells were lysed and processed as before for measurements
of internalized receptor.
For each internalization or recycling assessment, two controls were carried out.
To measure the total NRP1 or its variants at the surface, biotinylated cells at 4 °C
were lysed without biotin reduction. To verify the efﬁciency of the surface biotin
removal, the biotin reduction and MesNa quenching steps were carried out on cells
that had remained on ice (time 0) and lysis was carried out.
Equivalent volumes were analyzed by western blotting of NRP1 and
densitometric analyses. The percentages of internalized or recycled NRP1 and its
variants were calculated using the following formulae: internalized receptor =
(NRP1 or its variant level after ﬁrst incubation at 37 °C) ̶ (NRP1 or its variant level
at time 0)/(total surface NRP1 or its variant) × 100; recycled receptor = 100 ̶
[(NRP1 or its variant level after 15 min of re-incubation at 37 °C) ̶ (NRP1 or its
variant level at time 0)/(NRP1 or its variant level after ﬁrst incubation at 37 °C) ̶
(NRP1 or its variant level at time 0) × 100].

All data supporting the ﬁndings of this study are available within the article and
its supplementary information ﬁles and from the corresponding author upon reasonable
request. A reporting summary for this article is available as a Supplementary Information
ﬁle. The source data underlying Figs. 1d–f, 2a, d, e, g–i, 3c–h, 4a, b, f, 5b, c, e, f, h, 6a, b, d,
e, h, j, k, m, 7c, d, f–h and 8a, b, e-j, l and Supplementary Figs. 2a, b, e, h, 3c, e, g, i, j, 4c, d,
5a–d, f, g, 6a–c, g–i, k–m, 7c–g, 8a–d and 10a, d–j are provided as a Source Data ﬁle.

Enzyme-linked immunosorbent assay (ELISA). The concentration of HGF in
FBS and the FBS neutralized with bovine HGF antibody (NBP2-12355, Novus
Biologicals) was determined in triplicate wells using the Bovine HGF ELISA Kit
according to the manufacturer’s protocol (LifeSpan BioSciences).
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Cycloheximide chase assay. Cells were treated with cycloheximide (50 µgml−1)
and harvested at indicated time points. The cells were lysed in RIPA buffer and
equal amounts of total protein were analyzed by western blotting.
Cell growth assay. Cells (5 × 104/well) were seeded in 6-well plates in triplicate.
The number of viable cells was counted every day for 3 days using the Vi-CELL XR
2.03 (Beckman Coulter)58,60. Each experiment was performed in triplicate and
repeated at least three times.
Rac1 activity assay. Rac1 activity was assessed using the glutathione S-transferase
(GST)-tagged p21 binding domain of PAK1 (GST–PBD) pulldown assay61. Brieﬂy,
cells (2.5 × 106) were grown on collagen-precoated 6 cm dishes to ~70% conﬂuency
in regular growth medium containing 10% FBS, or serum starved overnight followed by stimulation with HGF (50 ngml−1) for 5 min. Subsequently, the cells were
lysed in lysis buffer (50 mM Tris, pH 7.4, 100 mM NaCl, 1% NP-40, 10% glycerol,
2 mM MgCl2, and protease and phosphatase inhibitor cocktails), and soluble
proteins were incubated with puriﬁed GST-PBD to pull down activated Rac1. The
amount of total and active Rac1 was detected using Rac1 antibody (Supplementary
Table 4).
Cell migration and invasion assays. Migration and invasion assays were performed in Boyden chambers coated with collagen or Matrigel, respectively60, as
instructed by the manufacturer (BD Biosciences). Brieﬂy, cells were added to the
upper chamber of the transwell insert. Complete medium containing 10% FBS,
HGF (50 ngml−1) or VEGF165 (50 ngml−1) as a chemoattractant was added to the
bottom chamber. To assess the effect of endocytosis and kinase inhibitors on cell
migration and invasion, the inhibitors or their vehicle control DMSO were added
to the bottom chamber medium. The plates were incubated at 37 °C in 5% CO2 for
indicated time periods. After incubation, cells in the upper compartment were
removed with a cotton swab, and cells that migrated or invaded to the ﬁlter surface
facing the bottom chamber were ﬁxed in 4% paraformaldehyde and stained with
0.2% crystal violet. The number of migrated or invaded cells were counted in at
least ﬁve areas at x 20 magniﬁcation using an inverted microscope.
In addition to the transwell migration assay, a time-lapse live cell imaging
system was used to record the migration of live cells. Cells were placed on collagenprecoated glass-bottom culture dishes and monitored at 37 °C using a Nikon
BioStation IMQ equipped with a CO2 incubation chamber. Time-lapse phase
images were taken every 30 min for 24 h. The movement of twenty individual cells
was tracked and analyzed using Nikon Element AR software.
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